CTLA4 and cancer: In addition, the results of immunogenomic analyses from The Cancer Immunome Atlas (TCIA) demonstrated that patients in the low ARL score group exhibited better responses to immunotherapy than patients in the high ARL score group, particularly when using CTLA4 targeted therapy alone, PD1 targeted therapy alone, or combined PD1 and CTLA4 targeted therapy, as well as targeted therapy excluding PD1 and CTLA4 (Figure 6F) (P < 0.05).